46 results about "Gangliocyte" patented technology

The subject invention pertains to deep learning (DL) systems and methods for the binary classification of Alzheimer's Disease. Optical coherence tomography (OCT) generated reports were used, and the images were grouped into 3 different inputs: (1) an optic nerve head (ONH) model including a retinal nerve fiber layer (RNFL) thickness map, a RNFL deviation map, and an ONH-centered en face image; (2) a Macula model including a ganglion cell inner plexiform layer (GCIPL) thickness map, a GCIPL deviation map, a macular thickness map, and a macula-centered en face image; and (3) a General model including all images of (1) and (2). A fusion network is provided to analyze the plurality of images from a single eye for classification. The fusion network includes Feature Extraction, Feature Fusion, and Feature Reconstruction. Ensemble learning is provided to advantageously combine several baseline models to build a single but more powerful model.

The invention discloses a retina bionics-driven super-resolution reconstruction model and an implementation method thereof. The reconstruction model is composed of a shallow extraction and lateral suppression module (LIM) and a deep feature extraction and reconstruction module (RM). The shallow layer extraction simulates the processing process of photoreceptor cells in a biological vision system on optical signals, and low-level feature information is extracted from a low-resolution image so as to realize primary processing of image signals; the side inhibition module LIM simulates a horizontal cell side inhibition mechanism to capture signals, and performs different intensity inhibition on features; the deep feature extraction adopts multi-layer feature fusion and a layered structure, imitates multiple functions of bipolar cells, gradually extracts and fuses feature information of different layers, and improves the naturalness of the whole image; the reconstruction module RM is composed of an up-sampling block and a convolution, simulates ganglion cells, and is responsible for generating a final high-resolution reconstruction image. According to the method, a satisfactory reconstruction result is obtained for an image in a complex scene, and meanwhile it is proved that a retina biological system is feasible to be migrated to an image super-resolution reconstruction technology.

Embodiments disclosed herein can provide ocular photo-bio- stimulation through light stimulation of specific wavelengths to the eye's retina, and to the entire eye's retina, the retina peripheral to the fovea, and / or the retina peripheral to the macula. In certain embodiments, the light stimulation is targeted at or to the rods. In other embodiments, the light stimulation is targeted at or to the ganglion cells or it is targeted at or to the rods and the ganglion cells, wherein the ganglion cells targeted or stimulated are the melanopsin containing ganglion cells (ipRGCs) or can also be called mRGCs.

The invention provides an optic nerve regulation and control system based on an ultrasonic technology, a first ultrasonic module is deployed on the outer side of a target human eyelid and is provided with an Archimedes spiral type first ultrasonic array facing the human eye, and the first ultrasonic array is configured to generate a gathered ultrasonic beam which acts on a human eye retina ganglion cell area in a targeted manner; the positioning module is deployed on the outer side of a target human eyelid and is configured to measure three-dimensional geometric data when a human eyeball horizontally faces the front and measure the depth distance of a human eye retina ganglion cell area in the human eye; the optic nerve response prediction module is pre-trained with an optic nerve response prediction model facing a target human body, and the optic nerve response prediction model is configured to adjust sound intensity output of the first ultrasonic array based on stimulation feedback prediction of human eye retina ganglion cells. According to the invention, the optic nerve regulation and control system satisfies non-intrusive, high-precision and self-adaptive requirements, and has optic nerve regulation and control and repair functions.

The present invention provides a biomarker combination for diagnosing Hirschsprung's disease, which is any one of combination 1, combination 2, and combination 3; wherein, the combination 1 is a combination of SCGN, PGP9.5, and S100; the combination 2 is a combination of SCGN and PGP9.5; the combination 3 is a combination of SCGN and S100. The present invention also provides the application of the above biomarker combination in the preparation of a diagnostic reagent for Hirschsprung's disease. At the same time, an immunohistochemistry kit is provided. The present invention discovers that SCGN can effectively identify ganglion cells in rectal mucosal biopsy specimens / entire colon specimens of children with Hirschsprung's disease, and the diagnostic sensitivity and specificity are higher than the existing detection schemes after combining with PGP9.5 and / or S100; the present invention provides a new, accurate, and sensitive detection method for the diagnosis of Hirschsprung's disease.

Provided are: a kit for inducing differentiation, which is for inducing the differentiation of a Muller glial cell into a retinal ganglion cell in vivo in a mammal; and a pharmaceutical composition for treating glaucoma or optic neuropathy. The kit and the pharmaceutical composition each include: a nucleic acid encoding NEUROG2; a combination of a nucleic acid encoding ASCL1, a nucleic acid encoding BRN3B, and a nucleic acid encoding ATOH7; or a combination of a nucleic acid encoding ASCL1, a nucleic acid encoding BRN3B, and a nucleic acid encoding ISL1.

The invention provides a compound for preventing and treating retinal ganglion cytopathy as well as a preparation method and application thereof, and particularly relates to the field of biological medicines. The invention provides a strain of Umbellopsisin A, the Umbellopsisin A metabolized by the Umbellopsisin A can significantly increase the number of viable retinal ganglion cells and also can improve visual conduction dysfunction, and the Umbellopsisin A can effectively pass through a blood retina barrier to achieve efficient prevention of omentum ganglion cell death, so that the Umbellopsisin A can be used for preparing medicines for treating retinal ganglion cell death. And retina injury can be repaired.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

Compositions, nucleic acid molecules, and methods for inducing retinal regeneration and reprogramming Muller glial cells (MGs) into retinal ganglion cells in a subject are described. The development of retina ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increases the MG neurogenesis capability induced by Ascl1. The combination of Ascl1, Pou4f2, and Islet1 stimulates the MG to produce bipolar cells and RGC-like neurons. Likewise, a transcription factor Onecut1, which is expressed in developing retinal cells but not expressed in MG, induces MG to produce RCG-like cells. Other transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. The MG-derived RGC can exhibit action potential in vivo, and exhibit chromatin characteristics similar to those of developing RGC.

The utility model discloses a retina chip, and relates to the technical field of medical instruments. The photosensitive layer is positioned on one side surface of the transparent substrate; the photosensitive layer is divided to form a plurality of photosensitive pixel units, and the plurality of photosensitive units are distributed in an array to form a photosensitive pixel array. A photosensitive layer is cut, so that a photosensitive pixel array is structurally segmented, and each photosensitive pixel unit is equivalent to a pixel point. Pixel cutting is carried out on the photosensitive layer to form pixel-like functional units, so that the functional units can effectively identify optical signals and generate corresponding stimulation current to ganglion cells, the structure is beneficial to more efficiently generate the optical signals and convert the optical signals into electric signals, and the image identification degree is increased.

The present invention provides use of lifitegrast in the preparation of a drug for treating retinal artery occlusion injury. Lifitegrast can effectively reduce retinal artery occlusion injury and apoptosis of retinal ganglion cells and has the effect of inhibiting inflammatory infiltration in the retina and activation of microglia. Moreover, lifitegrast has the effect of reducing retinal ganglion cell injury. Lifitegrast can be used for related diseases such as neuroinflammatory injury caused by retinal artery occlusion.

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

A method for determining if a tissue is ganglionic is provided. The method comprises a) generating at least one hyperspectral Raman image of a tissue from a region of interest in a tissue suspected to contain ganglion cells that was optionally identified by a method comprising autofluorescence (AF) and Second Harmonic generation (SHG) imaging of the tissue; and b) analyzing any of the images for one or more of the following: i) optical excitation; ii) chemical information or emission spectra; or iii) AF, SHG, and / or Raman signatures, wherein the analysis provides indicators that the region of interest is either ganglionic or non-ganglionic. A system for analysis of in vivo tissue or ex vivo tissue samples including a multiphoton autofluorescence microscope, a Second Harmonic Generation microscope, and a hyperspectral Raman microscope in operative communication is also provided.

The invention discloses application of upatinib in preparation of a medicine for treating acute retinal artery occlusion, and belongs to the field of biological medicine. Experimental verification shows that upatinib can remarkably relieve retina ischemia reperfusion injury caused by RAO and improve the survival and functional recovery of ganglion cells; by inhibiting JAK / STAT pathway mediated inflammatory cascade reaction, microglial cell M1 type polarization can be regulated, retinal inflammatory response can be inhibited, proinflammatory factor transcription and inflammatory diffusion can be reduced, and retinal nerve cell injury after RIR can be improved. The invention not only provides a new drug strategy of a targeting molecular mechanism for RAO treatment, but also provides a new theoretical basis for drug redevelopment and precise treatment of ischemic retinopathy, and has a wide application prospect.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

The present invention relates to reducing an activation of a trigeminal ganglion neuron or cell and related uses in treating or preventing migraine.

The application relates to a rapamycin-G4H nanocapsule, a preparation method and application thereof. The preparation method of the rapamycin-G4H nanocapsule comprises the following steps: S1. preparing a rapamycin micelle by adopting a film hydration method; S2. modifying a dibenzocyclooctyne amplification primer on the surface of the rapamycin micelle through a click chemistry reaction to obtain a rapamycin micelle modified with the amplification primer; S3. taking a linear DNA molecule as a template, and synthesizing a circular amplification template through an intramolecular cyclization reaction; and S4. incubating the circular amplification template, the rapamycin micelle modified with the amplification primer, a thermophilic DNA polymerase, a pyrophosphatase, dNTP and Co-G4-haem DNAzyme under the condition of a thermophilic DNA polymerase reaction buffer. The rapamycin-G4H nanocapsule can play an efficient antioxidant stress and immune inflammatory regulation function, can improve the intraocular microenvironment of a glaucoma patient, and can inhibit the continuous apoptosis of retinal ganglion cells.

The invention belongs to the field of biological medicines, and relates to a new pharmaceutical application of miR-126-3p. The invention discloses application of miR-126-3p or a functional equivalent thereof in preparation of a medicine for preventing or treating retinal structure damage and / or retinal function damage caused by retinal ischemia reperfusion injury caused by retinal artery occlusion. According to the medicine, by supplementing endogenous miR-126-3p consumed in the RIRI process, ganglion cell death can be reduced, and the retina structure can be protected; meanwhile, retina electrophysiological signals can be recovered, the retina function is improved, and therefore the core problem that in the prior art, vision of RAO patients is difficult to recover after blood recanalization is solved.

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

The invention belongs to the technical field of medicines, and particularly relates to application of a TASK-3 agonist or a TASK-3 overexpression biological product in preparation of a medicine for recovering a visual function and preventing and / or treating optic nerve injury. The TASK-3 selective agonist CHET3 disclosed by the invention can be used for inhibiting retinal ganglion cell injury induced by optic nerve extrusion, protecting the quantity of retinal ganglion cells and saving the visual function after injury. The invention also finds that the visual function of the optic nerve extrusion mouse can be recovered by specific overexpression of TASK-3 in the retinal ganglion cells. The invention provides a new treatment strategy for clinically improving the eyesight of a patient and delaying the disease progress, and has a wide application prospect in medical research and clinical practice of optic nerve injury.

This application discloses a display adjustment method and a display. The display adjustment method includes: obtaining a target biological cycle; determining a first target light intensity corresponding to a target blue light source in the display based on the target biological cycle; the light generated by the target blue light source acting on biological retinal ganglion cells; and adjusting the parameters of the display based on the first target light intensity so that the brightness, chromaticity, and display color of the display meet the target display effect and are adapted to the target biological cycle.

The application provides an application of YAP in preparation of a drug for preventing or treating retinal ganglion cell injury, and proves that up-regulation of YAP expression or activity can significantly reduce the retinal oxidative stress level, inhibit the neuroinflammatory response, and reduce the number of RGC death, thereby effectively protecting the nerve function. The application provides a new treatment target for diseases characterized by RGC injury, such as traumatic optic neuropathy and glaucoma, and YAP or an expression promoter thereof can be used for preparing a drug for preventing, relieving and / or treating the diseases, and has an important clinical application prospect.

The invention provides application of kushenone in preparation of a product for preventing and / or treating glaucoma, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the kushenone has the effect of preventing and / or treating glaucoma for the first time, can be used as a candidate medicine for treating acute glaucoma, can prevent ischemia reperfusion injury caused by acute intraocular pressure rise, and has the effect of inhibiting ferroptosis so as to play a role in protecting retinal ganglion cells; an effect can be achieved by inhibiting a cGAS-STING pathway and LCN2 expression, so that ferroptosis of microglial cells is inhibited.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The application discloses sgRNA targeting carbonic anhydrase 2 and application thereof. The sgRNA targeting carbonic anhydrase 2 comprises sgRNA as shown in SEQ ID NO. 1 and sgRNA as shown in SEQ ID NO. 2. The application develops sgRNA for double-site knockout of ciliary body Car2 based on CRISPR-Cas9 and AAV technology, realizes efficient Car2 targeting, has high knockout efficiency, effectively inhibits aqueous humor production, has obvious effect of reducing intraocular pressure and long maintenance time, significantly reduces retinal ganglion cell apoptosis, can be used for glaucoma treatment, and has wide application prospect.

The present invention relates to the technical field of ophthalmic drugs, and particularly relates to the use of loteprednol etabonate in the preparation of a drug for treating retinal artery occlusion injury. The present invention discovers a new use of loteprednol etabonate to solve the problem of lack of treatment means for retinal artery occlusion. Loteprednol etabonate can effectively reduce retinal artery occlusion injury and apoptosis of retinal ganglion cells. At the same time, loteprednol etabonate also has the effect of inhibiting retinal inflammatory infiltration and activation of microglia. Loteprednol etabonate also has the effect of reducing damage to retinal ganglion cells, can be used for related diseases such as neuroinflammatory injury of retinal artery occlusion, and has broad application prospects.

The present application belongs to the field of biological medicine research, and specifically provides the use of a transcription factor in one or more of the following: preparation of a retinal disease treatment drug; preparation of a retinal ganglion cell regeneration product; preparation of a product for inducing reprogramming of adult cells into retinal ganglion cells; preparation of a retinal ganglion cell; the transcription factor is selected from any one or more of Brn3B, Sox4, Atoh7, Sox11 and Isl1. The cell material used for the regenerated retinal ganglion cells is the endogenous cells of the self, and compared with the cell transplantation, there is no risk of immune rejection and tumorigenesis; the use of viral expression genes is simple and easy to popularize.

Composition and methods are provided for the treatment of a mammalian subject for axonopathies by increasing activity of axon regeneration-associated gene (RAG) as identified herein, which include without limitation ANXA2, TPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, AND ACAA2. These genes are shown to significantly promote axon regeneration, dramatically protects retinal ganglion cells and optic nerves, and preserve visual function in a clinically relevant model of glaucoma. A therapeutic entity may comprise, for example, a RAG protein, a gene therapy vector comprising a RAG coding sequence, a small molecule that enhances RAG activity, and the like.

The invention belongs to the technical field of cell protective agents, and particularly relates to a protective agent for in-vitro culture of mechanically damaged retinal ganglion cells as well as a preparation method and application of the protective agent. The protective agent is composed of etomidate, a protease inactivated substance and calcium chloride, and the ratio of etomidate to the protease inactivated substance to the calcium chloride is 1 mmol: (1-1.5) g: (0.1-0.5 mmol); the protease inactivated substance is a substance obtained by carrying out high-temperature inactivation on water-soluble protease; the temperature of the high-temperature inactivation is 120 DEG C to 140 DEG C. According to the invention, the protease inactivator and the calcium chloride are used for synergistic interaction on the etomidate, so that the protection effect on mechanically damaged retina neuronodule cells cultured in vitro is enhanced.